Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: IRAK1 is not required for PEL survival. (A) IRAK1 Western blot of BCBL-1Cas9 cell lines showing complete knockout; loading control is β-actin. (B) Growth curves for BCBL-1Cas9 ΔIRAK1 clones obtained via trypan blue cell counting. Two ΔIRAK1 clones and an empty vector control were used in this experiment. (C) Representative images from colony formation assays of ΔIRAK1 BCBL-1Cas9 cells imaged at ×10 magnification. Cells were plated at a low cell density in 1% methylcellulose medium and grown for 3 weeks. (D) Quantification of colony formation in BCBL-1Cas9 ΔIRAK1 stable cell lines. Colony counts were obtained using ImageJ, and the square root of the number of colonies was plotted; n = 15. (E) Flanking cut-site PCR analysis using PerkinElmer LabChip GX-Touch. Primers were designed flanking the cut site. Image analysis revealed changes in band size of the KO versus that of WT cells.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Knock-Out, Clone Assay, Cell Counting, Plasmid Preparation, Stable Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: MYD88, IRAK1, and IRAK4 are dispensable in BC-1 cells. (A) MYD88 Western blot of BC-1Cas9 cell lines showing complete knockout; loading control is β-actin. (B) IRAK1 Western blot. (C) IRAK4 western blot. (D) Growth curves for BC-1Cas9 ΔMYD88 clones obtained via trypan blue cell counting. Two ΔMYD88 clones and an empty-vector WT control were used in this experiment. (E) Growth curves for BC-1Cas9 ΔIRAK1 clones. (F) Growth curves for BC-1Cas9 ΔIRAK4 clones. (G) Quantification of colony formation in BCBL-1Cas9 ΔMYD88 stable cell lines. Colony counts were obtained using ImageJ, and the square root of the number of colonies was plotted; n = 15. (H) Quantification of colony formation in BCBL-1Cas9 ΔIRAK1 stable cell lines. (I) Quantification of colony formation in BCBL-1Cas9 ΔIRAK4 stable cell lines.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Knock-Out, Clone Assay, Cell Counting, Plasmid Preparation, Stable Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: NF-κB activation by IL-1β is not functional in ΔMYD88 clones. (A) A Western blot for phospho-NF-κB and the IRAK pathway proteins IRAK1, IRAK4 and MYD88 in WT and ΔMYD88 BCBL-1Cas9 cells 15 min post IL-1β stimulation (1 ng/μl IL-1β). (B) Quantification of luciferase production using an NF-κB reporter assays system. Two ΔMYD88 clones and WT BCBL-1Cas9 cells were stimulated with 1 ng/μl IL-1β, or mock PBS for 24 h h following transfection, and luciferase values measured 6 h h post stimulation. Results are fold change over mock. (C) Two ΔMYD88 clones and WT BCBL-1Cas9 cells were stimulated with TNF-α (1 ng/ml), and the response was compared to mock using the same procedure as in panel B.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Activation Assay, Functional Assay, Clone Assay, Western Blot, Luciferase, Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: Complementation of IRAK1 restores signaling function in KO cells. (A) Western blot in WT BCBL-1Cas9 cells showing expression of Myc-tagged IRAK1 in BCBL-1Cas9 cells. (B) IRAK expression plasmids were conucleofected with an NF-κB reporter-driven luciferase plasmid into WT or ΔIRAK1 BCBL-1Cas9 cells. Cells were stimulated with IL-1β or PBS (mock), and luciferase values were measured 6 h poststimulation. Shown are relative activities adjusted across multiple biological replicates and scales as fraction of maximal response on a log10 scale. (C) IRAK expression plasmids were conucleofected with an NF-κB reporter-driven luciferase plasmid into WT, ΔIRAK1, ΔIRAK4, or ΔMYD88 BCBL-1Cas9 cells. Cells were stimulated with IL-1β, TNF-α, or PBS (mock), and luciferase values were measured 6 h poststimulation. Shown are relative activities adjusted across multiple biological replicates and scales as fraction of maximal response on a log10 scale.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Expressing, Luciferase, Plasmid Preparation

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: Comparison of in vitro and in culture IRAK inhibitor activity. (A) EC50 curves (growth) for three commercially available IRAK inhibitors. Fraction of response is shown on the vertical axis and concentration (in μM) on the horizontal axis. Inh1 (CAS no. 1042224-63-4), Inh4 (CAS no. 1012104-68-5), and Inh1-4 (CAS no. 509093-47-4). The EC50 value on each plot is the average from four experiments. (B) Quantification of luciferase production in cells transfected with an NF-κB-driven luciferase plasmid, incubated with inhibitor, a nd stimulated with 1 ng/μl IL-1β. Luciferase values were measured 6 h poststimulation. All values are fold change over that with mock PBS stimulation on the vertical axis and inhibitor concentration (in μM) on the horizontal axis. (C) A DiscoverX KINOMEscan analysis for each IRAK inhibitor at 250 nM. Purple or blue dots and represent IRAK4 or IRAK1 kinase, respectively. Size of the circle is proportional to percent activity inhibited by the inhibitors.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: In Vitro, Activity Assay, Concentration Assay, Luciferase, Transfection, Plasmid Preparation, Incubation

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: IRAK1 is not required for PEL survival. (A) IRAK1 Western blot of BCBL-1Cas9 cell lines showing complete knockout; loading control is β-actin. (B) Growth curves for BCBL-1Cas9 ΔIRAK1 clones obtained via trypan blue cell counting. Two ΔIRAK1 clones and an empty vector control were used in this experiment. (C) Representative images from colony formation assays of ΔIRAK1 BCBL-1Cas9 cells imaged at ×10 magnification. Cells were plated at a low cell density in 1% methylcellulose medium and grown for 3 weeks. (D) Quantification of colony formation in BCBL-1Cas9 ΔIRAK1 stable cell lines. Colony counts were obtained using ImageJ, and the square root of the number of colonies was plotted; n = 15. (E) Flanking cut-site PCR analysis using PerkinElmer LabChip GX-Touch. Primers were designed flanking the cut site. Image analysis revealed changes in band size of the KO versus that of WT cells.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Knock-Out, Clone Assay, Cell Counting, Plasmid Preparation, Stable Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: MYD88, IRAK1, and IRAK4 are dispensable in BC-1 cells. (A) MYD88 Western blot of BC-1Cas9 cell lines showing complete knockout; loading control is β-actin. (B) IRAK1 Western blot. (C) IRAK4 western blot. (D) Growth curves for BC-1Cas9 ΔMYD88 clones obtained via trypan blue cell counting. Two ΔMYD88 clones and an empty-vector WT control were used in this experiment. (E) Growth curves for BC-1Cas9 ΔIRAK1 clones. (F) Growth curves for BC-1Cas9 ΔIRAK4 clones. (G) Quantification of colony formation in BCBL-1Cas9 ΔMYD88 stable cell lines. Colony counts were obtained using ImageJ, and the square root of the number of colonies was plotted; n = 15. (H) Quantification of colony formation in BCBL-1Cas9 ΔIRAK1 stable cell lines. (I) Quantification of colony formation in BCBL-1Cas9 ΔIRAK4 stable cell lines.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Knock-Out, Clone Assay, Cell Counting, Plasmid Preparation, Stable Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: NF-κB activation by IL-1β is not functional in ΔMYD88 clones. (A) A Western blot for phospho-NF-κB and the IRAK pathway proteins IRAK1, IRAK4 and MYD88 in WT and ΔMYD88 BCBL-1Cas9 cells 15 min post IL-1β stimulation (1 ng/μl IL-1β). (B) Quantification of luciferase production using an NF-κB reporter assays system. Two ΔMYD88 clones and WT BCBL-1Cas9 cells were stimulated with 1 ng/μl IL-1β, or mock PBS for 24 h h following transfection, and luciferase values measured 6 h h post stimulation. Results are fold change over mock. (C) Two ΔMYD88 clones and WT BCBL-1Cas9 cells were stimulated with TNF-α (1 ng/ml), and the response was compared to mock using the same procedure as in panel B.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Activation Assay, Functional Assay, Clone Assay, Western Blot, Luciferase, Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: Complementation of IRAK1 restores signaling function in KO cells. (A) Western blot in WT BCBL-1Cas9 cells showing expression of Myc-tagged IRAK1 in BCBL-1Cas9 cells. (B) IRAK expression plasmids were conucleofected with an NF-κB reporter-driven luciferase plasmid into WT or ΔIRAK1 BCBL-1Cas9 cells. Cells were stimulated with IL-1β or PBS (mock), and luciferase values were measured 6 h poststimulation. Shown are relative activities adjusted across multiple biological replicates and scales as fraction of maximal response on a log10 scale. (C) IRAK expression plasmids were conucleofected with an NF-κB reporter-driven luciferase plasmid into WT, ΔIRAK1, ΔIRAK4, or ΔMYD88 BCBL-1Cas9 cells. Cells were stimulated with IL-1β, TNF-α, or PBS (mock), and luciferase values were measured 6 h poststimulation. Shown are relative activities adjusted across multiple biological replicates and scales as fraction of maximal response on a log10 scale.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Expressing, Luciferase, Plasmid Preparation

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: Comparison of in vitro and in culture IRAK inhibitor activity. (A) EC50 curves (growth) for three commercially available IRAK inhibitors. Fraction of response is shown on the vertical axis and concentration (in μM) on the horizontal axis. Inh1 (CAS no. 1042224-63-4), Inh4 (CAS no. 1012104-68-5), and Inh1-4 (CAS no. 509093-47-4). The EC50 value on each plot is the average from four experiments. (B) Quantification of luciferase production in cells transfected with an NF-κB-driven luciferase plasmid, incubated with inhibitor, a nd stimulated with 1 ng/μl IL-1β. Luciferase values were measured 6 h poststimulation. All values are fold change over that with mock PBS stimulation on the vertical axis and inhibitor concentration (in μM) on the horizontal axis. (C) A DiscoverX KINOMEscan analysis for each IRAK inhibitor at 250 nM. Purple or blue dots and represent IRAK4 or IRAK1 kinase, respectively. Size of the circle is proportional to percent activity inhibited by the inhibitors.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: In Vitro, Activity Assay, Concentration Assay, Luciferase, Transfection, Plasmid Preparation, Incubation

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: IRAK1 is not required for PEL survival. (A) IRAK1 Western blot of BCBL-1Cas9 cell lines showing complete knockout; loading control is β-actin. (B) Growth curves for BCBL-1Cas9 ΔIRAK1 clones obtained via trypan blue cell counting. Two ΔIRAK1 clones and an empty vector control were used in this experiment. (C) Representative images from colony formation assays of ΔIRAK1 BCBL-1Cas9 cells imaged at ×10 magnification. Cells were plated at a low cell density in 1% methylcellulose medium and grown for 3 weeks. (D) Quantification of colony formation in BCBL-1Cas9 ΔIRAK1 stable cell lines. Colony counts were obtained using ImageJ, and the square root of the number of colonies was plotted; n = 15. (E) Flanking cut-site PCR analysis using PerkinElmer LabChip GX-Touch. Primers were designed flanking the cut site. Image analysis revealed changes in band size of the KO versus that of WT cells.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Knock-Out, Clone Assay, Cell Counting, Plasmid Preparation, Stable Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: MYD88, IRAK1, and IRAK4 are dispensable in BC-1 cells. (A) MYD88 Western blot of BC-1Cas9 cell lines showing complete knockout; loading control is β-actin. (B) IRAK1 Western blot. (C) IRAK4 western blot. (D) Growth curves for BC-1Cas9 ΔMYD88 clones obtained via trypan blue cell counting. Two ΔMYD88 clones and an empty-vector WT control were used in this experiment. (E) Growth curves for BC-1Cas9 ΔIRAK1 clones. (F) Growth curves for BC-1Cas9 ΔIRAK4 clones. (G) Quantification of colony formation in BCBL-1Cas9 ΔMYD88 stable cell lines. Colony counts were obtained using ImageJ, and the square root of the number of colonies was plotted; n = 15. (H) Quantification of colony formation in BCBL-1Cas9 ΔIRAK1 stable cell lines. (I) Quantification of colony formation in BCBL-1Cas9 ΔIRAK4 stable cell lines.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Knock-Out, Clone Assay, Cell Counting, Plasmid Preparation, Stable Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: NF-κB activation by IL-1β is not functional in ΔMYD88 clones. (A) A Western blot for phospho-NF-κB and the IRAK pathway proteins IRAK1, IRAK4 and MYD88 in WT and ΔMYD88 BCBL-1Cas9 cells 15 min post IL-1β stimulation (1 ng/μl IL-1β). (B) Quantification of luciferase production using an NF-κB reporter assays system. Two ΔMYD88 clones and WT BCBL-1Cas9 cells were stimulated with 1 ng/μl IL-1β, or mock PBS for 24 h h following transfection, and luciferase values measured 6 h h post stimulation. Results are fold change over mock. (C) Two ΔMYD88 clones and WT BCBL-1Cas9 cells were stimulated with TNF-α (1 ng/ml), and the response was compared to mock using the same procedure as in panel B.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Activation Assay, Functional Assay, Clone Assay, Western Blot, Luciferase, Transfection

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: Complementation of IRAK1 restores signaling function in KO cells. (A) Western blot in WT BCBL-1Cas9 cells showing expression of Myc-tagged IRAK1 in BCBL-1Cas9 cells. (B) IRAK expression plasmids were conucleofected with an NF-κB reporter-driven luciferase plasmid into WT or ΔIRAK1 BCBL-1Cas9 cells. Cells were stimulated with IL-1β or PBS (mock), and luciferase values were measured 6 h poststimulation. Shown are relative activities adjusted across multiple biological replicates and scales as fraction of maximal response on a log10 scale. (C) IRAK expression plasmids were conucleofected with an NF-κB reporter-driven luciferase plasmid into WT, ΔIRAK1, ΔIRAK4, or ΔMYD88 BCBL-1Cas9 cells. Cells were stimulated with IL-1β, TNF-α, or PBS (mock), and luciferase values were measured 6 h poststimulation. Shown are relative activities adjusted across multiple biological replicates and scales as fraction of maximal response on a log10 scale.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: Western Blot, Expressing, Luciferase, Plasmid Preparation

Journal: Journal of Virology

Article Title: Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma

doi: 10.1128/JVI.02123-19

Figure Lengend Snippet: Comparison of in vitro and in culture IRAK inhibitor activity. (A) EC50 curves (growth) for three commercially available IRAK inhibitors. Fraction of response is shown on the vertical axis and concentration (in μM) on the horizontal axis. Inh1 (CAS no. 1042224-63-4), Inh4 (CAS no. 1012104-68-5), and Inh1-4 (CAS no. 509093-47-4). The EC50 value on each plot is the average from four experiments. (B) Quantification of luciferase production in cells transfected with an NF-κB-driven luciferase plasmid, incubated with inhibitor, a nd stimulated with 1 ng/μl IL-1β. Luciferase values were measured 6 h poststimulation. All values are fold change over that with mock PBS stimulation on the vertical axis and inhibitor concentration (in μM) on the horizontal axis. (C) A DiscoverX KINOMEscan analysis for each IRAK inhibitor at 250 nM. Purple or blue dots and represent IRAK4 or IRAK1 kinase, respectively. Size of the circle is proportional to percent activity inhibited by the inhibitors.

Article Snippet: We obtained three IRAK1 expression plasmids from OriGene, namely, pDD1951 (RC221544, PEL phenotype full-length IRAK1), pDD1952 (RC224107, IRAK1 isoform B), pDD1953 (RC204869, IRAK1 isoform C), and the empty vector control pDD1957 (EV, pCMV6-entry).

Techniques: In Vitro, Activity Assay, Concentration Assay, Luciferase, Transfection, Plasmid Preparation, Incubation